CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,048 enrolled
Drug / intervention
Brolucizumab ophthalmic solution +1 moredrug
Likely dose
Brolucizumab ophthalmic solution 6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02434328
NCT02434328Phase 3Completed
CompareCT.gov

A Two-year, Randomized, Double-masked, Multicenter, Two-arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects With Neovascular Age-related Macular Degeneration

Alcon Research·interventional·Posted May 5, 2015·Updated Jan 16, 2025

In Brief

A Phase 3 clinical trial evaluating Brolucizumab ophthalmic solution and Aflibercept ophthalmic solution for Neovascular Age-Related Macular Degeneration and Choroidal Neovascularization. Completed, enrolled 1,048 participants.

Detailed Summary

The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection (6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 5, 2015
Enrollment StartJul 28, 2015
Primary CompletionApr 5, 2017
Study CompletionMar 8, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.2 years ago

Interventions

Brolucizumab ophthalmic solutiondrug

Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose

Aflibercept ophthalmic solutiondrug

Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose